ALIMERA SCIENCES INC
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$81M
Investors
16
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
ALIMERA SCIENCES INC is an entity organized in Delaware that first filed a Form D on February 18, 2014 and most recently amended it on September 26, 2024. The offering claims Securities Exchange Act of 1934. ALIMERA SCIENCES INC reported $81,000,000 sold from 16 investors as of the Form D filed September 26, 2024. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 6310 Town Square, Suite 400, Alpharetta, GA 30005.
EDGAR Filing Data
Form 15 / Schedule TO — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Sep 26, 2024
Critical / warning
0 / 1
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
2
closed
Latest event Exchange act deregistration · Sep 26, 2024
SEC.govInvestor
- 1 filing event with values and deltas, latest 2024-09-26, and alerts on the next one
- 2 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-05-31: 2 related persons added and 2 removed against the filing of 2023-04-07; 11 now listed. The names are in the Terminal feed.
Richard S. Eiswirth, Jr.
Executive Officer, Director · Alpharetta, GA
Philip S. Ashman
Executive Officer · Alpharetta, GA
David S. Holland
Executive Officer · Alpharetta, GA
Russell S. Skibsted
Executive Officer · Alpharetta, GA
Garheng S. Kong
Director · Alpharetta, GA
Daniel S. Myers
Director · Alpharetta, GA
Adam S. Morgan
Director · Alpharetta, GA
Erin S. Parsons
Director · Alpharetta, GA
Michael S. Kaseta
Director · Alpharetta, GA
Peter J. Pizzo III
Director · Alpharetta, GA
John J. Snisarenko
Director · Alpharetta, GA
Questions About ALIMERA SCIENCES INC
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is ALIMERA SCIENCES INC?
ALIMERA SCIENCES INC is an issuer that filed a Form D with the SEC on September 26, 2024. The filing claims Securities Exchange Act of 1934.
Is ALIMERA SCIENCES INC legit?
AltStreet does not rate legitimacy; it reports the public record. ALIMERA SCIENCES INC filed a Form D with the SEC on September 26, 2024 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $81,000,000 sold to 16 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is ALIMERA SCIENCES INC registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that ALIMERA SCIENCES INC claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has ALIMERA SCIENCES INC raised?
ALIMERA SCIENCES INC reported $81,000,000 sold from 16 investors as of the Form D filed September 26, 2024.
Who is selling ALIMERA SCIENCES INC and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind ALIMERA SCIENCES INC?
The Form D lists 11 related persons: Richard S. Eiswirth, Jr., executive officer, director; Philip S. Ashman, executive officer; David S. Holland, executive officer; Russell S. Skibsted, executive officer; Garheng S. Kong, director; Daniel S. Myers, director; Adam S. Morgan, director; Erin S. Parsons, director, and 3 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is ALIMERA SCIENCES INC located?
The issuer's address on its SEC filings is 6310 Town Square, Suite 400, Alpharetta, GA 30005. Its phone number of record is 678-990-5740. It is organized under the laws of Delaware.
How long is the ALIMERA SCIENCES INC offering open?
An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.